Skip to content
MARKETS / NASDAQ / PRE
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Prenetics Global Ltd. PRE

5 fiscal years on record · USD · FY2024 reported · SEC filings only
$30.6M
▲ 40.8% YoY
$-46.3M
$-29.9M
In brief

What this company does

We are a consumer health company advancing human health and longevity through science-backed products, global brand partnerships, and AI-driven operations. Our flagship brand, IM8—co-founded with David Beckham—generated $60.1 million in revenue in its first full fiscal year, achieved $120 million in ARR as of December 2025, and ships to more than 30 countries. Following our strategic transformation throughout 2025 and into 2026, our business is organized around two brands:

Written from the business description in Prenetics Global Limited's annual report to the U.S. Securities and Exchange Commission, filed 30 April 2026. Every sentence was checked against that document before publication.

Growth
USD 30.6M
Revenue, FY2024 · full 5-year series below
Revenue $M Net income $M
FY2024 · Revenue 30.6 · Net income -46.3
25.0M50.0M-80.0M-160.0M20202021202220232024
Compound annual growth
+34.7%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−163 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -157.2% · Net -162.7%
-500%-1000%20202021202220232024
ROE
FY2024 · ROE -24.6%
-10%-20%20202021202220232024

Each USD of equity lost 25 cents this year.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -29.9
4M8M-10M-20M20202021202220232024

Total assetsUSD 213.6M
EquityUSD 170.4M
CashUSD 52.3M
Current ratio2.36×

Equity funds 80% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20242023202220212020
Revenue $B0.00.00.00.00.1
Operating income $B−0.0−0.1−0.1−0.1−0.0
EBITDA $B·····
Income tax $B−0.0−0.0−0.00.0−0.0
Net income $B−0.0−0.1−0.2−0.2−0.0
Free cash flow $B−0.0−0.00.00.0−0.0
EPS, diluted $−3.71−5.58−37.57−178.81−0.15
Dividend / sh $·····
Payout %·····
ROE %−24.6−28.3···
Shares out B0.010.01···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 23 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 72 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image